{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:15Z","timestamp":1792686255358,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Tall cell variant (TCV) represents the predominant aggressive subtype of papillary thyroid carcinoma (PTC). This study aimed to precisely characterize the evolving survival prognosis of these patients using extensive long-term follow-up data from a large cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a cohort of 1004 eligible TCV patients diagnosed from 2004 to 2016 were included in this investigation. Conditional survival (CS) analysis was used to describe the evolving nature of survival changes for long-term TCV survivors. Following this, the cohort was divided into training and validation sets using a 7:3 ratio. The least absolute shrinkage and selection operator (LASSO) model was utilized to identify prognostically significant factors, which were subsequently integrated to construct a CS-nomogram model. Multiple evaluation methods, including calibration curves, the area under the receiver operating characteristic (ROC) curve, C-index, and decision curve analysis (DCA), were employed to assess the performance of this model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among included patients, the Kaplan\u2013Meier method estimated a 10-year OS rate at diagnosis of 85%. In contrast, the CS analysis revealed annual increases, with survival rates improving from 85% at the initial diagnosis to 88%, 90%, 91%, 92%, 94%, 95%, 97%, 99%, and 99% for patients surviving 1 to 9 years after diagnosis, respectively. Through LASSO regression analysis, this study identified age, sex, N status, M status, AJCC stage, tumor size, surgery and radioactive iodine as key predictors for developing the CS-based nomogram. Calibration curves, ROC curves, C-index values, and DCA further determined nomogram model\u2019s effectiveness and reliability. Moreover, based on this CS-nomogram, we calculated risk scores for each patient and used risk scores to categorized patients into high- and low-risk groups in both training and validation cohorts. The Kaplan-Meier analysis with log-rank tests further validated the prognostic discriminative power of our risk stratification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The findings of our study comprehensively outlined the 10-year CS outcomes for TCV patients, revealing a steady increase in 10-year OS corresponding to each additional year of survival in TCV survivors. We also developed a CS-nomogram model, an individualized tool integrating time-varying covariates and patient-specific characteristics delivers real-time prognostic information tailored to each TCV patient.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1517907","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T05:26:11Z","timestamp":1742793971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Dynamic survival outcomes of the tall-cell variant of papillary thyroid carcinoma patients after surgery"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuxiang","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.30725","article-title":"Utilizing dynamic risk stratification in patients with tall cell variant papillary thyroid cancer","volume":"133","author":"David","year":"2023","journal-title":"Laryngoscope"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072152","article-title":"Outcomes of the tall-cell variant of papillary thyroid carcinoma in patients with different ages: A 17-year mono-institutional experience","volume":"15","author":"Agnese","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000559","article-title":"Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma","volume":"27","author":"Sara","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0164","article-title":"Papillary thyroid carcinoma tall cell variant","volume":"18","author":"Ronald","year":"2008","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2022.3781","article-title":"Risk factors associated with recurrence and death in patients with tall cell papillary thyroid cancer: A single-institution cohort study with predictive nomogram","volume":"149","author":"Shannon","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01391-1","article-title":"Papillary thyroid cancer-aggressive variants and impact on management: A narrative review","volume":"37","author":"Andr\u00e9s","year":"2020","journal-title":"Adv Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000184","article-title":"Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid","volume":"25","author":"Meryl","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad580","article-title":"Effect of radioactive iodine therapy on cancer-specific survival of papillary thyroid cancer tall cell variant","volume":"109","author":"Dai","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2129-x","article-title":"Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients","volume":"19","author":"Hadiza","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01949-6","article-title":"A nomogram and risk classification system for predicting cancer-specific survival in tall cell variant of papillary thyroid cancer: a SEER-based study","volume":"46","author":"Wang","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-018-9561-4","article-title":"Tall cell variant of papillary thyroid carcinoma: impact of change in WHO definition and molecular analysis","volume":"30","author":"Kristine","year":"2019","journal-title":"Endocr Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0563","article-title":"Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis","volume":"23","author":"Eric","year":"2013","journal-title":"Thyroid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy143","article-title":"Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO\/ARO\/AIO-04 randomized phase III trial","volume":"29","author":"Fokas","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12672-024-01042-9","article-title":"A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic colorectal cancer","volume":"15","author":"Pei","year":"2024","journal-title":"Discov Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001239","article-title":"Conditional probability of survival after neoadjuvant chemoradiation and proctectomy for rectal cancer: what matters and when","volume":"62","author":"Georgios","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00384-024-04614-x","article-title":"Conditional survival analysis and real-time prognosis prediction in stage III T3-T4 colon cancer patients after surgical resection: a SEER database analysis","volume":"39","author":"Hao","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2017.1405012","article-title":"Statistical methods for conditional survival analysis","volume":"28","author":"Sin-Ho","year":"2017","journal-title":"J Biopharm Stat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28273","article-title":"Dynamic prognostication using conditional survival estimates","volume":"119","author":"Emily","year":"2013","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-14983-w","article-title":"Conditional survival of patients with limited-stage small cell lung cancer after surgery: A national real-world cohort study","volume":"31","author":"Lin","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"106957","DOI":"10.1016\/j.ejso.2023.06.009","article-title":"Risk-dependent conditional survival analysis and annual hazard rate of inflammatory breast cancer","volume":"49","author":"Meng","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1049531","article-title":"Conditional survival analysis and real-time prognosis prediction for cervical cancer patients below the age of 65 years","volume":"12","author":"Xiangdi","year":"2023","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Vinod","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.05.054","article-title":"Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm","volume":"171","author":"Simon","year":"2021","journal-title":"Surgery"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1517907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T05:26:14Z","timestamp":1742793974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1517907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":23,"alternative-id":["10.3389\/fendo.2025.1517907"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1517907","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"article-number":"1517907"}}